^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

bleomycin

Company:
Generic mfg.
Drug class:
DNA synthesis inhibitor
Related drugs:
4d
Long-Term Disease-Free Survival After Sorafenib-Combined Chemotherapy for Refractory Metastatic Testicular Germ Cell Tumor: A Five-Year Follow-Up. (PubMed, J Med Cases)
While first-line BEP (bleomycin, etoposide, cisplatin) chemotherapy achieves high cure rates in most patients, those who progress after multiple lines of therapy have a poor prognosis and limited treatment options, highlighting a critical gap in effective treatment decision-making for advanced disease...He then experienced rapid progression with new lung and brain metastases that were unresponsive to second-line GEMOX (gemcitabine + oxaliplatin) chemotherapy and a programmed death-ligand 1 (PD-L1) blockade clinical trial...Guided by a molecular tumor board (MTB) recommendation, an off-label regimen of carboplatin, paclitaxel, and sorafenib (CPS) was initiated, targeting the MAPK pathway...Tumors are highly complex, and gene-cancer interaction is still being elucidated. In this context, key learning points from this case include: 1) the critical role of iterative molecular profiling and MTB guidance in identifying actionable targets when standard options are exhausted; 2) the potential value of rational drug rechallenge informed by the evolving "tumor ecology;" and 3) the necessity of long-term follow-up to link treatment responses with biomarkers, allowing N-of-1 learning that may offer a template for personalized management in similarly challenging cases.
Journal • PD(L)-1 Biomarker • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase)
|
cisplatin • carboplatin • gemcitabine • sorafenib • paclitaxel • oxaliplatin • etoposide IV • bleomycin
6d
Topical bleomycin treatment of oral proliferative verrucous leukoplakia: a pilot study (ChiCTR2500113466)
P=N/A, N=13, Completed, Peking University Hospital of Stomatology; Peking University Hospital of Stomatology
New trial
|
bleomycin
7d
Peroxiredoxin 1 mediates bleomycin-induced acute lung injury in mice via macrophage NOD1/NF-κB axis. (PubMed, Respir Res)
These findings identify Prdx1 as a potential therapeutic target for BLM-induced ALI, offering a strategy to mitigate its pulmonary toxicity and facilitate the broader clinical application of BLM.
Preclinical • Journal
|
PRDX1 (Peroxiredoxin 1)
|
bleomycin
7d
Postmenopausal Stage IV Ovarian Yolk Sac Tumor With Neuroendocrine Features: Report of a Rare Case. (PubMed, Anticancer Res)
This case illustrates a particularly rare and aggressive presentation of ovarian YST in a postmenopausal patient. Early recognition, accurate pathological characterization, and individualized treatment are essential, although prognosis remains poor in this setting. Reporting such cases is crucial to improve understanding and management of these exceptional tumors.
Journal
|
CHGA (Chromogranin A)
|
cisplatin • etoposide IV • bleomycin
7d
Targeted Sensitization of Leukemic T-cells to Anticancer Drugs by SIRT1 Agonist SRT-1720. (PubMed, Anticancer Res)
SRT-1720 induces oxidative stress and apoptosis in leukemic lymphocytes through SIRT1-independent pathway(s). In contrast, it enhances antioxidant defense in normal lymphocytes through a SIRT1-dependent pathway. These findings highlight the potential of SRT-1720 as an adjuvant to chemotherapy in T-ALL, particularly in drug combinations demonstrating strong synergism, which may allow dose reduction and decreased toxicity.
Journal
|
SIRT1 (Sirtuin 1)
|
cisplatin • Ibrance (palbociclib) • everolimus • bortezomib • doxorubicin hydrochloride • bleomycin • ABT-737 • MG132 • barasertib (AZD1152)
17d
Succinate-mediated activation of the GPR91/MALT1/NF-κB/CCL2 pathway in macrophages contributes to pulmonary fibrosis. (PubMed, Int Immunopharmacol)
Succinate triggers CCL2 release in macrophages via the GPR91/MALT1/NF-κB pathway, thereby exacerbating pulmonary fibrosis. These findings suggest that targeting succinate signaling may represent a novel therapeutic strategy for IPF.
Journal
|
MALT1 (MALT1 Paracaspase) • CCL2 (Chemokine (C-C motif) ligand 2) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • SUCNR1 (Succinate Receptor 1)
|
bleomycin
21d
Histopathologic diagnosis of mediastinal seminoma in a low-resource setting: A case report on navigating limited access to molecular testing. (PubMed, Int J Surg Case Rep)
The patient subsequently received 3 cycles of bleomycin, etoposide, and cisplatin (BEP) chemotherapy. This case highlights the importance of diagnostic adaptability, multidisciplinary care, and long-term follow-up in achieving successful outcomes for rare thoracic malignancies. Broader lessons include the value of pragmatic decision-making, judicious use of limited diagnostic tools, and structured follow-up strategies that can guide clinicians facing similar challenges in resource-limited environments.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
|
cisplatin • etoposide IV • bleomycin
25d
Establishment and characterization of a testicular yolk sac tumor PDX model. (PubMed, Clin Transl Oncol)
We successfully established a TYST PDX model that retains tissue structure and protein expression signature of the patient's tumor tissue. Furthermore, this PDX model demonstrates high sensitivity to standard JEB chemotherapy and represents a valuable resource for translational research in pediatric germ cell tumors.
Journal
|
AFP (Alpha-fetoprotein) • SALL4 (Spalt Like Transcription Factor 4)
|
carboplatin • etoposide IV • bleomycin
28d
Effect of Bleomycin Hydrolase Expression in Tumor Tissue on the Therapeutic Effectiveness of Electrochemotherapy. (PubMed, Cancers (Basel))
Measuring BLMH levels may help stratify patients and personalize ECT application; however, it is not the sole factor for response prediction. Future studies in clinical tumor samples are warranted to evaluate its predictive value and to develop integrated biomarker models.
Journal
|
BLMH (Bleomycin Hydrolase)
|
bleomycin
28d
Potentiation of Electrochemotherapy by Anti-PD-1 Immunotherapy in Murine Tumors with Distinct Immune Profiles. (PubMed, Cancers (Basel))
ECT synergizes with PD-1 blockade to potentiate local and systemic antitumor immunity, overcoming immune resistance in poorly immunogenic tumors. These findings support further clinical development of ECT in combination with immune checkpoint inhibitors as a component of personalized cancer immunotherapy.
Preclinical • Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • GZMB (Granzyme B)
|
bleomycin
1m
Spil-mediated sEH overexpression contributes to the senescence of alveolar epithelial cells during pulmonary fibrosis in mice. (PubMed, J Mol Med (Berl))
We have reported that EETs inhibit AEC senescence, alleviating bleomycin (BLM)-induced PF in mice...Inhibition of Spi1 significantly attenuated AEC senescence. Inhibition of Spi1 alleviated pulmonary fibrosis in aging mice.
Preclinical • Journal
|
SPI1 (Spi-1 Proto-Oncogene)
|
bleomycin
1m
Mechanistic insights into Moringa oleifera leaf bioactive against cytotoxic stress: an integrative approach. (PubMed, Toxicol Mech Methods)
This study investigates the radioprotective potential of MO leaf extract against DNA damage induced by bleomycin and X-irradiation...Furthermore, molecular docking and 200 ns molecular dynamics simulations revealed that kaempferol, a major MO constituent, exhibited strong binding affinity with the Keap1-Nrf2 complex, suggesting activation of antioxidant gene expression. Overall, the findings support MO's role as a natural, low-toxicity radioprotective agent and highlight the complementary value of computational approaches alongside cytogenetic assays in validating therapeutic potential.
Journal
|
KEAP1 (Kelch Like ECH Associated Protein 1)
|
bleomycin